-- UGN-301 is an investigational immunotherapy designed for monotherapy and combination therapy in treating low-grade and high-grade disease -- PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 1, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing
PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 28, 2022-- UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual
--Investigator’s Retrospective Analysis Published in the Journal of Urology Provides Protocol for Antegrade Administration of Jelmyto , the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer-- PRINCETON, N.J. --(BUSINESS WIRE)--Feb.
-- ENVISION Study Design Similar to Successful UGN-102 Phase 2b OPTIMA II Trial -- PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers,
PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 5, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare
Study explores opportunity to shift from clinic to home instillation of this promising non-surgical treatment Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 21, 2021-- UroGen Pharma Ltd.
PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 3, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to
Shift to single-arm Phase 3 study for UGN-102 in bladder cancer streamlines pivotal study to form basis of FDA submission Jelmyto® net product revenue of $11.4 million for the third quarter of 2021; New patient starts in September and October outpace July and August by nearly 60% Conference call
PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 11, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare
New, Single-arm Phase 3 Study Expected to Initiate in Early 2022 PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 10, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, is announcing at
